Study guide
16.4 Genital Herpes, Syphilis & Anogenital Warts
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
16.4 Genital Herpes, Syphilis & Anogenital Warts
Key Takeaways Explain This Topic AI
Type-specific HSV PCR on an active lesion swab is the diagnostic gold standard and is far more sensitive than viral culture.
A recurrent herpes outbreak is preceded by a sensory prodrome of tingling or neuralgic pain 12 to 24 hours before vesicles appear.
The primary syphilitic chancre is solitary, painless, indurated, and clean-based, and it resolves spontaneously while spirochetes disseminate.
Condylomata lata of secondary syphilis are moist flat gray-white plaques and must be distinguished from the verrucous condylomata acuminata caused by HPV types 6 and 11.
Podofilox, podophyllin, sinecatechins, and imiquimod are not used for warts in pregnancy; cryotherapy, trichloroacetic acid, and surgical removal are acceptable, and cesarean is not indicated to prevent transmission.
Last updated: September 2026
Genital Herpes Simplex Virus (HSV-1 & HSV-2)
Genital herpes is a lifelong viral infection characterized by neurotropic latency within the dorsal root sacral sensory ganglia (S2–S4) .
Primary (Initial) Episode: Severe, bilateral clusters of painful vesicles on an erythematous base that rapidly rupture into exquisitely tender, shallow, non-indurated ulcerative lesions. Accompanied by systemic symptoms: high fevers, headaches, malaise, severe bilateral inguinal lymphadenopathy, and dysuria (frequently precipitating acute urinary retention). Lesions persist for 2 to 3 weeks.
Recurrent Episodes: Viral reactivation traveling retrogradely down sensory axons. Unilateral, milder, localized clusters with fewer lesions that heal within 5 to 7 days. Typically preceded by a characteristic sensory prodrome (tingling, burning, paresthesias, or neuralgic pain in the buttocks or vulva 12 to 24 hours prior to vesicle eruption).
Diagnostic Modalities: Type-specific HSV Polymerase Chain Reaction (PCR) performed on active lesion swabs is the gold standard (vastly superior to viral culture). Type-specific glycoprotein G IgG serology distinguishes HSV-1 from HSV-2.
Pharmacologic Management:
Primary Episode: Acyclovir 400 mg PO TID for 7 to 10 days , OR Valacyclovir 1 g PO BID for 7 to 10 days .
Episodic Recurrent Outbreaks: Initiated during the prodrome or within 24 hours of lesion eruption: Valacyclovir 500 mg PO BID for 3 days, or Valacyclovir 1 g PO daily for 5 days.
Daily Suppressive Therapy: For individuals with frequent recurrences (≥6 per year), severe emotional distress, or to reduce transmission to discordant partners: Valacyclovir 500 mg or 1 g PO once daily .
Obstetric Management & Transmission Prevention:
Primary HSV acquisition in late pregnancy carries a catastrophic 30% to 50% risk of vertical neonatal transmission (disseminated disease, encephalitis).
Recurrent HSV at labor carries a much lower transmission risk (1% to 3%) due to protective transplacental maternal IgG.
Universal Suppression Protocol: All pregnant individuals with a documented personal history of genital HSV (regardless of recurrence frequency) must initiate daily antiviral suppression at 36 weeks gestation ( Acyclovir 400 mg PO TID or Valacyclovir 500 mg PO BID ) and continue through delivery to prevent clinical recurrences at term.
Delivery Route: At labor onset, perform a meticulous vulvar and perineal speculum inspection. If active genital lesions or prodromal symptoms are present, cesarean delivery is mandatory to prevent direct neonatal viral contact during descent.
Syphilis: Staging, Serology & Gestational Management
Syphilis is a systemic chronic infection caused by the spirochete Treponema pallidum .
Clinical Staging & Manifestations
Primary Syphilis: Hallmark is the chancre —a solitary, painless, indurated, clean-based ulcer with raised, rolled borders appearing at the inoculation site 10 to 90 days (average 21 days) post-exposure. Accompanied by painless, non-suppurative regional lymphadenopathy. Resolves spontaneously within 3 to 6 weeks without treatment, giving a false impression of cure while spirochetes disseminate hematogenously.
Secondary Syphilis: Develops 4 to 10 weeks after the primary chancre, reflecting systemic bacteremic dissemination. Hallmarks include:
Highly characteristic diffuse, symmetrical, non-pruritic maculopapular rash involving the palms of the hands and soles of the feet .
Condylomata lata: Large, moist, flat-topped, highly infectious, cauliflower-like gray-white plaques in warm, intertriginous areas (vulva, perineum, perianal region).
Mucous patches in oral cavity, generalized painless lymphadenopathy, patchy "moth-eaten" alopecia, low-grade fever, and malaise.
Latent Syphilis: Seropositive without clinical signs. Subdivided into:
Early Latent: Acquired within the preceding 12 months.
Late Latent / Unknown Duration: Infection duration ≥1 year, or unknown timing.
Tertiary Syphilis: Occurs decades later in untreated individuals: destructive gummatous lesions of bone and soft tissue, cardiovascular syphilis (ascending aortic aneurysms, aortic insufficiency), and neurosyphilis.
Serologic Diagnostic Testing Algorithms
Traditional Algorithm: Initial screening with a non-treponemal antibody test ( RPR or VDRL ), which measures anticardiolipin antibodies. Titers (e.g., 1:32) correlate with disease activity and treatment response (a four-fold change in titer, such as from 1:32 to 1:8, confirms therapeutic cure). All reactive non-treponemal tests must be confirmed with a specific treponemal test ( FTA-ABS or TP-PA ), which detects antibodies directed specifically against T. pallidum proteins and typically remains positive for life.
Reverse Sequence Algorithm: Initial screening with an automated treponemal antibody enzyme immunoassay (EIA) or chemiluminescence immunoassay (CIA). If positive, reflex quantitative RPR is performed. If RPR is non-reactive, a second distinct treponemal test (TP-PA) is performed to resolve discordance.
CDC Recommended Treatment Protocols
Primary, Secondary, & Early Latent Syphilis:
Benzathine Penicillin G 2.4 million units IM in a single dose .
Late Latent, Latent of Unknown Duration, or Tertiary Syphilis (with normal CSF):
Benzathine Penicillin G 2.4 million units IM once weekly for 3 consecutive weeks (total cumulative dose: 7.2 million units).
The Invalidation Rule: In non-pregnant individuals, if the interval between weekly doses exceeds 14 days, the entire 3-week course must be restarted. In pregnant patients , the interval must not exceed 7 to 9 days ; if a dose is delayed beyond 9 days, the entire 3-week series must be restarted from Day 1!
The Jarisch-Herxheimer Reaction
An acute, self-limiting systemic inflammatory response occurring within 2 to 24 hours of initiating penicillin therapy, triggered by the massive, simultaneous lysis of spirochetes releasing pyrogenic endotoxins. Manifests with acute fevers, chills, rigors, tachycardia, myalgias, and transient exacerbation of cutaneous lesions. In pregnant individuals, it can induce intense uterine contractions, preterm labor, and transient fetal heart rate decelerations. Treatment is supportive (antipyretics, hydration); patients must be reassured that this is an expected physiological reaction, not an allergic drug reaction.
[!CRITICAL] Mandatory Gestational Penicillin Rule: Penicillin G is the ONLY proven antimicrobial agent that effectively treats maternal syphilis, crosses the placenta in therapeutic concentrations, and cures congenital syphilis in the fetus. If a pregnant patient has a documented anaphylactic or severe penicillin allergy , non-penicillin alternatives (e.g., doxycycline, erythromycin, azithromycin) are strictly contraindicated or therapeutically ineffective. The certified nurse-midwife must coordinate immediate admission to an inpatient monitored unit for oral or IV penicillin desensitization , followed immediately by the standard gestational Benzathine penicillin G regimen!
Anogenital Warts (Condylomata Acuminata)
HPV types 6 and 11 cause about 90% of anogenital warts . These are low-risk types: warts are a cosmetic and psychological burden, not a precancerous lesion, and a wart is not an indication for colposcopy.
Diagnosis is clinical. Biopsy when the lesion is pigmented, indurated, fixed, ulcerated, bleeding, atypical, or fails to respond to treatment , and in any immunocompromised patient. Do not apply acetic acid to "screen" normal skin for subclinical HPV — it generates false positives and anxiety without benefit.
Treatment Options
No treatment eradicates HPV; all of them remove visible lesions, and recurrence in the first 3 months is common . Untreated warts may also resolve spontaneously, so observation is a legitimate choice .
Patient-Applied Provider-Applied
Imiquimod 3.75% or 5% cream (immune response modifier) Cryotherapy with liquid nitrogen , repeated every 1–2 weeks
Podofilox 0.5% solution or gel (antimitotic) Trichloroacetic or bichloroacetic acid 80–90% , applied weekly to the lesion only
Sinecatechins 15% ointment (green tea catechins) Surgical removal: excision, electrocautery, or laser
Caution
In pregnancy: podofilox, podophyllin, sinecatechins, and imiquimod are not recommended. Acceptable options are cryotherapy, trichloroacetic or bichloroacetic acid, and surgical removal . Warts often enlarge in pregnancy and frequently regress postpartum. Cesarean birth is not indicated to prevent transmission — it is reserved for warts that obstruct the outlet or would cause excessive bleeding. Juvenile-onset recurrent respiratory papillomatosis is rare and is not prevented by cesarean.
Prevention: the 9-valent HPV vaccine covers types 6 and 11 along with the oncogenic types 16, 18, 31, 33, 45, 52, and 58 — so the same vaccine that prevents cervical cancer prevents most genital warts.